Chongzhao Ran1, Zhaoda Zhang, Jacob Hooker, Anna Moore. 1. Molecular Imaging Laboratory, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA 02129, USA.
Abstract
PURPOSE: The poor tissue penetration of visible light has been a major barrier for optical imaging, photoactivatable conversions, and photodynamic therapy for in vivo targets with depths beyond 10 mm. In this report, as a proof-of-concept, we demonstrated that a positron emission tomography (PET) radiotracer, 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)FDG), could be used as an alternative light source for photoactivation. PROCEDURES: We utilized (18)FDG, which is a metabolic activity-based PET probe, as a source of light to photoactivate caged luciferin in a breast cancer animal model expressing luciferase. RESULTS: Bioluminescence produced from luciferin allowed for the real-time monitoring of Cherenkov radiation-promoted uncaging of the substrate. CONCLUSION: The proposed method may provide a very important option for in vivo photoactivation, in particular for activation of photosensitizers for photodynamic therapy and eventually for combining radioisotope therapy and photodynamic therapy.
PURPOSE: The poor tissue penetration of visible light has been a major barrier for optical imaging, photoactivatable conversions, and photodynamic therapy for in vivo targets with depths beyond 10 mm. In this report, as a proof-of-concept, we demonstrated that a positron emission tomography (PET) radiotracer, 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)FDG), could be used as an alternative light source for photoactivation. PROCEDURES: We utilized (18)FDG, which is a metabolic activity-based PET probe, as a source of light to photoactivate caged luciferin in a breast cancer animal model expressing luciferase. RESULTS: Bioluminescence produced from luciferin allowed for the real-time monitoring of Cherenkov radiation-promoted uncaging of the substrate. CONCLUSION: The proposed method may provide a very important option for in vivo photoactivation, in particular for activation of photosensitizers for photodynamic therapy and eventually for combining radioisotope therapy and photodynamic therapy.
Authors: K Berg; P K Selbo; A Weyergang; A Dietze; L Prasmickaite; A Bonsted; B Ø Engesaeter; E Angell-Petersen; T Warloe; N Frandsen; A Høgset Journal: J Microsc Date: 2005-05 Impact factor: 1.758
Authors: Barbara J Fueger; Johannes Czernin; Isabel Hildebrandt; Chris Tran; Benjamin S Halpern; David Stout; Michael E Phelps; Wolfgang A Weber Journal: J Nucl Med Date: 2006-06 Impact factor: 10.057
Authors: Robin S Dothager; Reece J Goiffon; Erin Jackson; Scott Harpstrite; David Piwnica-Worms Journal: PLoS One Date: 2010-10-11 Impact factor: 3.240
Authors: Gregory S Mitchell; Ruby K Gill; David L Boucher; Changqing Li; Simon R Cherry Journal: Philos Trans A Math Phys Eng Sci Date: 2011-11-28 Impact factor: 4.226
Authors: Adam K Glaser; Rongxiao Zhang; Jacqueline M Andreozzi; David J Gladstone; Brian W Pogue Journal: Phys Med Biol Date: 2015-08-13 Impact factor: 3.609